Estimation of some Inflammatory Markers in Covid-19 Patients in Erbil-City

Shayma Kh. Muhammed  
Suhaila N. Darogha  
Department of Biology/ College of Education/ Salahaddin University/ Erbil

ABSTRACT

The 2019 pandemic coronavirus disease has affected millions of individuals globally. The objective of the present study is to assess the possible predictors of CoV-2 severity and to identify the possible correlation between patients' parameters and disease severity. Consequently, we aimed to measure the serum levels of some inflammatory markers, including CRP, D-dimer, Ferritin, and Procalcitonin, as a biomarker for disease severity in CoV-2 patients. A total of 280 nasopharyngeal swabs and whole blood specimens were collected from healthy individuals and individuals suspected with CoV-2 between June 2021 and December 2021 of both sexes, categorized into four main groups: 70 healthy individuals with an age range (23-70), 210 CoV-2 patients in which their ages were between (21-75), (70 patients per mild, moderate and severe patients). According to our findings CoV-2 patients’ groups had leukocytosis, with a significant increase in WBC and Granulocytes count, and a significant decrease in Lymphocyte and platelet. In regard to inflammatory parameters, CRP, D-dimer, ferritin and PCT showed significant differences between the CoV-2 patients groups compared to the control group, these inflammatory biomarkers were significantly elevated in CoV-2 patients group compared to healthy control group (P<0.005). The optimal cut-off values for CRP, D-dimer, Ferritin, and PCT were determined by Receiver Operating Characteristic (ROC) Curve Analysis in CoV-2 patients. In conclusion, Inflammation biomarkers are the best predictors of severe CoV-2, and the combination of clinical signs can further predict severe CoV-2.

Keywords: COVID-19, SARS-CoV-2, CoV-2 Pandemic, Hematological parameter, Inflammatory biomarkers.
INTRODUCTION

The novel coronavirus (COVID-19) known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first appeared in Wuhan city, China, on 31 December 2019 and then rapidly spread throughout the world including Iraq (Mutlk et al., 2021). A pandemic of SARS-CoV-2 was subsequently declared by the WHO (Boserup et al., 2020). Globally, more than 528 million individuals (2,328,264 in Iraq) had contracted the disease as of the first of June 2022, and about 6.3 million people had died, counting 25,219 in Iraq (Organization, 2022). Patients are categorized into mild, moderate, severe, and critical cases based on their clinical symptoms and the results of laboratory tests (Sharma et al., 2021; Wu and McGoogan, 2020).

The carry-out of biological markers enables a further certain interpretation of the disease's course. Leukocytes, CRP, ferritin, interleukin-6, and D-dimer are the primary indicators of inflammatory reactions (Lippi and Favaloro, 2020; Zheng et al., 2020). The body may respond by creating an excessive number of cytokines as a consequence of the inflammatory response brought on by CoV-2, leading to the condition known as a cytokine storm (Grasseli et al., 2020; Ji et al., 2020).

C-reactive protein is a sensitive early indicator of tissue damage, infection, and inflammation that is generated by IL-6 in the liver. The amount of CRP expression rises considerably and quickly from its normal low level in acute inflammatory response (Mooiweer et al., 2011; Hhan et al., 2018). Treatment of severe CoV-2 patients benefits by monitoring the concentrations of inflammatory markers like CRP and IL-6 (Qin et al., 2020).

D-dimer is discovered to be the fibrin breakdown product mediated by soluble plasmin and initiated by the start of the coagulation and fibrinolysis cascade (Zhou et al., 2020). In individuals with CoV-2, it has been described as one of the most prevalent and quickly raised laboratory results linked with coagulopathy (Organization, 2022). In these patients, a striking relationship demonstrating the prognostic significance of D-dimer is the significant synergy between CoV-2 infection and venous thromboembolism (Kariyanna et al., 2020).

As an "acute phase reactant," serum Ferritin reflects the severity of both chronic and acute inflammatory responses within the body. The direct immunosuppressive and pro-inflammatory consequences of a greater Ferritin level, which is a sign of an activated monocyte-macrophage system, could lead to a cytokine storm (Kernan and Carcillo, 2017; Vargas and Cortès-Rojo, 2020). Serum Ferritin is a protein that storage iron whose main function is to control cellular oxygen consumption (Chen et al., 2022). In the situation of the development of CoV-2, serum ferritin has lately acquired significance as a biomarker for inflammation, as shown by earlier studies in this area (Kell and Pretorius, 2014; Cheong et al., 2020).

Procalcitonin is a glycoprotein with non-hormonal activity produced by thyroid parafollicular C cells (Choi and McCarthy, 2018). It can also be produced after bacterial infection in a variety of extrathyroid tissues, which is mediated by elevated levels of TNF-alpha and IL-6 (Lippi and Cervellin, 2018). In healthy individuals, the serum PCT level is below detectable, but systemic inflammations, particularly those brought on by bacterial infections, cause the amount to rise (Floriańczyk, 2003). Recently, multiple investigations found an inverse relationship between high PCT and CoV-2 severity (Guan et al., 2020; Zhang et al., 2020). This study aimed to assess the value of some inflammatory biomarkers, including serum CRP, D-dimer, ferritin, and PCT in the early diagnosis and CoV-2 severity.

MATERIALS AND METHODS

Subjects

Two hundred and ten individuals who were tested positive for CoV-2 infection by reverse transcription-quantitative (RT-q) PCR of nasal or pharyngeal swab specimens in three hospitals (Rozhawa emergency, Emirati and lalav intensive care unit (ICU)) in Erbil city were comprised in this study. The patients were classified into three groups, 70 patients (35 female and 35 male) were complaining of mild symptoms and treated as outpatients, while another 140 patients were admitted
to the hospital, 70 of them (39 female and 31 male) complaining from moderate symptoms while 70 of them complaining from severe symptoms (38 female and 32 male) in which their ages were between (21-75), in addition to 70 healthy control (27 female and 43 male) with age range (23-70).

Blood Samples
After receiving written informed consent from all participants, a sample of venous blood (about 5 ml) was promptly taken from every CoV-2 patient and healthy persons’ subject enrolled in this trial and placed into two separate laboratory tubes. Two ml of the blood in a test tube with EDTA was used for the measurement of a vital haematological parameter using an automated haematology analyser (Medonic mserries, sweden) to determine WBC, Granulocytes, Lymphocytes, Platelets, and Haemoglobin. The rest three ml of the whole blood was collected in a serum separating gel tube for 30 minutes to coagulate. The samples were centrifuged at 5,000 RPM for 5 minutes to collect serum for CRP and D-Dimer analysis using INDIKO PLUSE Instrument (Fenland), Ferritin levels were determined by Cobase 411 – Roche (Germany) and Procalcitonin (PCT) analysis using the enzyme-linked immunosorbent assay (ELISA) (Biotech, Germany).

Statistical Analysis
The data was analyzed using a (Graph Pad prism 9.0), variables with a normally distribution were appropriately reported as mean ± SD. Statistical significance was defined as a P value 0.05. The data of haematological parameters and inflammatory markers presented of this study, the (ANOVA) and person correlation test was used to evaluate between-group comparisons for categorical variables, the predictive significance of the study determine severity via receiver operating characteristic (ROC) curve analyses and the results were expressed as area under curve (AUC), cut-off value, specificity and sensitivity. The symbol (*) refer to highly significantly difference between patient groups and healthy control; (ns) refer to non-significant between groups.

RESULTS AND DISCUSSION
The CoV-2 is characterized by acute respiratory distress syndrome, is brought on by the unique coronavirus SARS-COV-2, which is a multisystem disease caused by the incorporation of immunological, inflammatory, and coagulative cascades. The clinical appearance of CoV-2 ranges from asymptomatic to critical pneumonia, acute respiratory distress syndrome, and even death (Wiersinga et al., 2020). During the worldwide CoV-2 pandemic, the role of laboratory medicine for clinical decision-making and evaluation of biomarkers for early prediction of the severity and mortality was markedly highlighted. In general, inflammatory markers as CRP, D-dimer, and PCT are accepted as important infection biomarkers of severe CoV-2 disease (Zhang et al., 2020).

Evaluation of Hematological Parameters of SARS-CoV-19
Although we still know very little about the exact adaptive and innate immune response to SARS-CoV-2, the hematological changes might be a homeostatic defense against systemic inflammation that has been over activated (Allegra et al., 2020; Li et al., 2020). Sars-cov-2’s progression and frequency depend on the relation between the viral cells and the immune cells of the organism (Younis and Fattah, 2021).

According to our findings CoV-2 patients’ group had leukocytosis, WBC and Granulocyte count were elevated significantly with the severity of the disease, while Lymphocyte numbers decreased with severity in comparison with the control group. Regarding Monocyte cells, there was a non-significant difference between the CoV-2 groups compared to the control group, as shown in (Table 1).

The immune system in our bodies consists of two lines of defense against pathogens: the first line, known as WBC, which attacks foreign bodies within minutes to hours through direct ingestion via a process known as phagocytes; the second line, known as antibodies, and T lymphocytes, which produce chemicals that attack viruses, are the two lines of defense. (Marquez et al., 2020).
Other studies that confirm our findings demonstrate that CoV-2 patients had greater WBC counts than the healthy group, particularly in the more severe cases (Lu et al., 2021; Jalil et al., 2022).

Our studies indicated lower lymphocyte counts and higher Granulocyte counts in CoV-2 groups compared to the healthy control group, which may be related to increased inflammation brought on by bacterial infection and immune system suppression brought on by CoV-2 infection (Waris et al., 2021). According to several studies, Lymphopenia affects between 40% and 91.6% of CoV-2 patients, and it has been recommended that this condition may be used as a prognostic indicator (Zhao et al., 2020). Our results are consistent with earlier research, which found that lymphocytopenia served like an efficient and dependable biomarker for the intensity of CoV-2 disease and was frequently associated with (SARS-CoV and MERS-CoV-2) infection (Elshazli et al., 2020; Tang et al., 2020). In accordance with our investigation, studies of Sánchez-Cerrillo et al. (2020) and Pirsalehi et al. (2021) revealed that CoV-2 patients had a marked decline in monocyte count.

In our immune system, platelets have an important function in blood clotting and are known to play a part. They are also a major controller of inflammatory illnesses (Aktaş et al., 2013). Several proposed mechanisms for the thrombocytopenia brought on by CoV-2: Megakaryocyte and bone marrow suppression by a direct viral infection and inflammatory cytokines. CoV-2 patients’ thrombocytopenia is brought on by lung damage because mature megakaryocytes, which are present in the lung, release platelets (Rizo-Téllez et al., 2020; Wool and Miller, 2021). Studies Bashash et al. (2020), showed the predictive relevance of platelet count in this illness. They show in their meta-analysis of 19 studies that a lower count of platelet is linked to a higher danger of contracting serious disease. Our study found that the platelet there was a comparison of the results reveals that highly significant difference between CoV-2 cases compare to healthy cases, which was lower count of platelet especially in severe cases, that was similar to the other founding studies (Bashash et al., 2020).

**Table 1: Comparison of hematological parameters between healthy and COVID-19 cases**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Category of COVID-19 cases</th>
<th>p. value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Moderate</td>
<td>Severe</td>
<td></td>
</tr>
<tr>
<td>WBC (10^9/l)</td>
<td>6.99±2.02</td>
<td>9.59±5.02</td>
<td>13.15±5.71</td>
</tr>
<tr>
<td>Lym (10^9/l)</td>
<td>2.09±0.69</td>
<td>1.02±0.54</td>
<td>0.94±0.55</td>
</tr>
<tr>
<td>Mono (10^9/l)</td>
<td>0.57±1.03</td>
<td>0.53±0.82</td>
<td>0.79±1.01</td>
</tr>
<tr>
<td>Gran (10^9/l)</td>
<td>4.29±1.62</td>
<td>8.08±4.78</td>
<td>11.41±5.30</td>
</tr>
<tr>
<td>HGB (g/dl)</td>
<td>14.05±1.65</td>
<td>13.71±1.55</td>
<td>12.71±1.81</td>
</tr>
<tr>
<td>PLT (10^9/l)</td>
<td>219.48±59.89</td>
<td>247.31±96.84</td>
<td>292.46±120.94</td>
</tr>
</tbody>
</table>

The mean difference is significant at the 0.05 level

Combined letters: mean no significant differences between groups

**Evaluation of Inflammation Markers of Covid-19**

CoV-2 reasons of a systemic inflammatory response leading to release of various inflammatory biomarkers in the body. Escalating levels of inflammatory biomarkers lead to increasing severity of CoV-2 illness (Huang et al., 2020).

The current study found that the CRP level was highly significantly increase in severe patients compared to moderate and mild patients and the control group but there was a non-significant difference between mild and moderate. The optimal Cut-off values of CRP for predicting severity in CoV-2 patients were determined via (ROC) Curve analysis was for mild 6.100 mg/l (sensitivity= 75.71%; specificity=87.14%; (AUC )=0.847), moderate 7.535 mg/l (sensitivity=94.29%; specificity=97.14%; AUC=0.970) and sever 7.855 mg/l (sensitivity= 100%; specificity=97.14%; AUC=1.000) (Table 2) and Fig. (1).

The result of our study is consistent with those of Li et al. (2020) and Qin et al. (2020), who found that more severe instances of CoV-2 expressed larger CRP levels than non-severe patients, and suggestive of CRP level may be a biomarker of disease severity and progression in CoV-2
patients. Ji et al. (2020), suggested that one of the earliest biomarkers to represent physiological difficulties and the most significant biomarker for determining whether CoV-2 would advance was CRP levels.

Table 2: Comparison of inflammatory markers between healthy and COVID-19 cases

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Category of COVID-19 cases</th>
<th>p. value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mild</td>
<td>Moderate</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>3.74±2.33a</td>
<td>34.11±31.57bc</td>
<td>47.44±26.69c</td>
</tr>
<tr>
<td>D-dimer (µg/ml)</td>
<td>0.92±0.20ab</td>
<td>2.18±1.60b</td>
<td>7.21±2.49c</td>
</tr>
<tr>
<td>Ferritin (ng/ml)</td>
<td>96.96±72.98a</td>
<td>999.9±918.3bc</td>
<td>1071±648.4cd</td>
</tr>
<tr>
<td>PCT (pg/ml)</td>
<td>55.13±46.93</td>
<td>88.70±39.73</td>
<td>164.7±58.44</td>
</tr>
</tbody>
</table>

The mean difference is significant at the 0.05 level
Combined letters: mean no significant differences between groups

Considering the markers of coagulation, the results showed D-dimer is the most significant marker of covid-19 patients, our results showed a highly increase significant in the level of D-dimer between severe patients compare to mild, moderate, and control groups, but there was a non-significant difference between mild and control group. The optimal Cut-off values of D-dimer for predicting severity in CoV-2 patients were determined via ROC Curve analysis were mild 0.74 µg/ml (sensitivity= 100%; specificity=97.14%; AUC=0.995), moderate 0.76 µg/ml (sensitivity=100%; specificity=97.14%; AUC=1.000) and sever 0.76 µg/ml (sensitivity= 100%; specificity=97.14%; AUC=1.000) p=0.000 (Table 2, 3) and Fig. (2).

Our study's findings are consistent with those of a number of other studies. Tang et al. (2020), reported that CoV-2 patients with a severe illness had D-dimer levels approximately 3.5 times higher than those with only mild or moderate illness. Wang et al. (2020) and Huang et al. (2020), who reported that CoV-2 patients with a severe level of illness had 2.5 times and 5 times higher levels of D-dimer than patients with only mild or moderate levels of illness, respectively. Because inflammatory cytokines may cause imbalances between coagulation and fibrinolysis in the alveoli, which may subsequently activate the fibrinolysis system and raise D-dimer levels, the
rise in D-dimer levels may be an indirect sign of an inflammatory response (Sharma et al., 2021). Inflammatory storm activation and plasma release of proinflammatory cytokines like IL-7, IL-2, G-CSF, MCP-1, IP-10, MIP-1A, and TNF- may be the cause of the D-dimer level elevation. The endothelial dysfunction mechanism is triggered, resulting in damage to the microvascular system and activation of the coagulation system, which raises the D-dimer value. (He et al., 2021).

Fig. 2. A: Comparison of D-dimer level in patient group and healthy control. B: ROC curve of D-dimer level

The elevated ferritin level was a highly significant increase between (mild to moderate and severe) compared to the control group, but there was a high difference and non-significant difference between mild to moderate and moderate to severe that is showed in Fig. (3). The optimal Cut-off values of Ferritin for predicting severity in CoV-2 patients were determined via ROC Curve analysis were mild 162.1 ng/ml (sensitivity=91.43%; specificity=87.14%; AUC=0.932), moderate 167.3 ng/ml (sensitivity = 90%; specificity = 92.86%; AUC=0.917) and severe 278.3 ng/ml (sensitivity = 92.86%; specificity = 97.14%; AUC=0.928) (Table 2, 3) and Fig. (3).

CoV-2 patients with serious illness exhibited higher ferritin levels compared to those with mild to moderate disease. This surplus could lead to a secondary bacterial infection and exacerbate CoV-2 illness. Our findings are consistent with evidence from other studies that have established a link between blood ferritin and the CoV-2 seriousness. Mohammed Saeed et al. (2020); Bozkurt et al. (2021); Maghfirah et al. (2020), in their research found that serum Ferritin levels and the severity of CoV-2 have a significant association with a strong positive correlation; this means that patients of CoV-2 experience more serious symptoms, which is greater than their serum ferritin levels. As an “acute-phase protein”, ferritin is frequently increased in many different inflammatory responses and could be a clear sign of cellular damage (Kell and Pretorius, 2014; Henry et al., 2020). Several variables, including older age, sex, genetics, and iron consumption, influenced the CoV-2 case's ferritin rate (Mckinnon et al., 2014). High ferritin serum levels are discovered during infection and may signify viral replication. In a severe case of CoV-2, an increase in ferritin rate brought on by a cytokine storm has been documented (Chen et al., 2020).
Procalcitonin was a highly significant increase between the three groups of CoV-2 patients when compared with the group of control. The optimal Cut-off values of PCT for predicting severity in CoV-2 patients were determined via ROC Curve analysis for mild 66.09 pg/ml (sensitivity = 82.86%; specificity = 78.57%; AUC = 0.832), moderate 97.13 pg/ml (sensitivity = 90%; specificity = 90%; AUC = 0.877), and severe 119.8 pg/ml (sensitivity = 100%; specificity = 92.86%; AUC = 0.963) (Table 2, 3 and Fig. 4).

As a consequence of our research, we determined that patients with severe cases had mean serum PCT levels that were about four times higher than those with moderate cases and eight times greater than those with light cases. PCT level may be a sign of how severe a condition is and may help assess how seriously CoV-2 patients are affected. All of our findings are consistent with previous research. Lippi and Plebani (2020), in their meta-analysis discovered that patients with CoV-2 had approximately 5-fold greater probability of developing the serious disease when their serum PCT levels were higher. Furthermore, the authors hypothesized that routine evaluation of the procalcitonin level would be useful in foretelling the development of CoV-2 to a more extreme condition. Vazzana et al. (2022), revealed that, on average, patients with a severe CoV-2 course had higher PCT levels than those with a non-severe course.

Along with CRP and interleukin IL-6, PCT is another inflammatory biomarker frequently checked in CoV-2 patients. Leukocytes and different parenchymal cells in the lungs, fat, and liver, in addition to leukocytes in reaction to proinflammatory cytokines and endotoxins, produce PCT (Meisner, 2014; Ponti et al., 2020). Procalcitonin can be used to diagnose or predict certain diseases, because interferon-c prevents PCT production, serum concentrations in viral infections are thought to be consistently low, as well (Schuetz et al., 2011). The PCT levels of most individuals with CoV-2 are very low at arrival, while increased inflammatory markers like WBC and CRP show that their lungs are inflamed (Guan et al., 2020; Xu et al., 2020).

However, as the condition progresses, the PCT levels rise, which may be associated to the prevalence of bacterial infections. In these patients, secondary bacterial pneumonia could develop due to the co-infection with bacteria and the viral illness (Rawson et al., 2020). It has been established that co-infection with bacteria is a plausible cause for higher PCT in individuals with severe CoV-2 and dead patients with CoV-2 were more likely to experience multiple organ failure or co-infection (Wang et al., 2020).
To correlate PCT values with other inflammatory biomarkers, the Pearson correlation coefficient was calculated, and the results are shown in (Table 4). PCT displayed a highly significant positive correlation with hemoglobin in the mild group and a highly significant negative correlation with platelet, Lymphocyte, and CRP (P<0.01), while PCT displayed a highly significant positive correlation with Lymphocyte and a significant negative correlation with platelet and Ferritin in moderate group. In the severe group, there was a highly negative correlation with D-dimer and a positive correlation with hemoglobin (p<0.01 and p<0.05) respectively.
Table 4: Correlation of PCT with hematological and inflammatory markers among Covid-19 patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mild</th>
<th>Patients’ categories</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pearson</td>
<td>P. value</td>
<td>Pearson</td>
<td>P. value</td>
</tr>
<tr>
<td></td>
<td>correlation</td>
<td></td>
<td>correlation</td>
<td></td>
</tr>
<tr>
<td>Age (year)</td>
<td>0.039</td>
<td>0.748</td>
<td>0.005</td>
<td>0.965</td>
</tr>
<tr>
<td>WBC (10^9/l)</td>
<td>-0.116</td>
<td>0.337</td>
<td>-0.066</td>
<td>0.585</td>
</tr>
<tr>
<td>Lym (10^9/l)</td>
<td>-0.243*</td>
<td>0.042</td>
<td>0.342**</td>
<td>0.004</td>
</tr>
<tr>
<td>Mono (10^9/l)</td>
<td>-0.014</td>
<td>0.911</td>
<td>-0.072</td>
<td>0.551</td>
</tr>
<tr>
<td>Gran (10^9/l)</td>
<td>-0.090</td>
<td>0.457</td>
<td>-0.094</td>
<td>0.441</td>
</tr>
<tr>
<td>HGB (g/dl)</td>
<td>0.396**</td>
<td>0.001</td>
<td>-0.151</td>
<td>0.213</td>
</tr>
<tr>
<td>PLT (10^9/l)</td>
<td>-0.357**</td>
<td>0.002</td>
<td>0.282*</td>
<td>0.018</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>-0.246*</td>
<td>0.040</td>
<td>0.039</td>
<td>0.746</td>
</tr>
<tr>
<td>D-dimer (µg/ml)</td>
<td>0.066</td>
<td>0.585</td>
<td>-0.014</td>
<td>0.907</td>
</tr>
<tr>
<td>Ferritin (ng/ml)</td>
<td>-0.158</td>
<td>0.192</td>
<td>-0.254*</td>
<td>0.034</td>
</tr>
</tbody>
</table>

*: Correlation is significant at the 0.01 level (2-tailed).  
**: Correlation is significant at the 0.05 level (2-tailed).

CONCLUSION

In conclusion, CRP, D-dimer, Ferritin, PCT and platelets can efficiently assess the severity of CoV-2. It is the most effective forecaster of severe Covid-19, and the combination of the clinical markers can further predict severe CoV-2. Therefore, it is suggested that these markers be utilized to quickly detect severe disease in CoV-2 patients in order to assist the early start of effective treatment. Additionally, the dynamics of inflammatory markers in CoV-2 patients might be serve as a helpful marker for the change from a mild to a severe infection.

REFERENCES


Findings from the SHIELD study. *Nutrients*, **12**(11), 3329. https://doi.org/10.3390/nu12113329


Kell, D.B.; Pretorius, E. (2014). Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. *Metallomics*, **6**(4), 748-773. Doi: 10.1039/c3mt00347g


تقدير بعض المعلمات الالتهابية لدى مرضى كوفيد-19 في مدينة أربيل

شيماء خليل محمد
قسم علوم الحياة/كلية التربية/ جامعة صلاح الدين/ أربيل

الملخص

أثر مرض فيروس كورونا الوبائي لعام 2019 على ملايين الأفراد على مستوى العالم. كان الهدف من الدراسة الحالية هو تقييم المتغيرات المحتملة لشدة مرض CoV-2 وتحديد العلاقة المحتملة بين معلمات المرضي وشدة المرض، وبالتالي، كان نهدف فحص Procalcitonin و Ferritin و D-Dimer و CRP.perm CocH من البمعوم الأنفي وعينات دم كاممة من الأفراد الأصحاء والأفراد المشتبه في إصابتهم بفيروس CoV-2 بين حزيران 2021 و كانون الأول 2021 من كلا الجنسين، مصنفة إلى أربع مجموعات رئيسية: 70 فردًا سليمًا تتراوح أعمارهم بين (23-70)، 210 مريضا ب-CoV-2 كانت أعمارهم بين (21-75)، (70 فرد لكل اصابة خفيفة، اصابة معتدلة واصابة شديدة). وفقًا للنتائج التي توصلنا إليها، كانت هناك ارتفاع معنوي في عدد الكريات الدم البيضاء وعدد الخلايا الوارقة وانخفاض معنوي في عدد الخلايا المحببة والصفائح الدموية لدى مجموعات مرضى CoV-2. مقارنة بالمجموعة التحكم الصحية. حيث ارتفعت مستوى هذه المعلمات معنويًا لدى مرضى CoV-2 مقارنة بالمجموعة التحكم الصحية، (P < 0.05). تم تحديد قيم القطع الموثقة ل PCT و Ferritin و D-dimer و CRP من خلال تحليل منحنى خصائص تشتت جهاز الاستقلال (ROC) فيكawe. و أخيراً فإن المؤشرات الحيوية للالتهابات تعتبر هي أفضل للتنبؤ بالإصابة ب-CoV-2 الشديد. ويمكن أن يؤدي الجمع بين العلامات السريرية إلى التنبؤ بشكل أكبر ب-CoV-2 الشديد. ويمكن للمؤشرات الحيوية للالتهابات تقييم شدة CoV-2 بدقة.

الكلمات الدالة: CoV-2، SARS-CoV-2، جائحة CoV-2، معلمات أمراض الدم، المؤشرات الحيوية الالتهابية.